Unbound MEDLINE

WT1 and Bcl2 expression in melanocytic lesions of the conjunctiva: an immunohistochemical study of 123 cases. Archives of ophthalmology [Arch Ophthalmol] Journal article

 
TitleWT1 and Bcl2 expression in melanocytic lesions of the conjunctiva: an immunohistochemical study of 123 cases.
Author(s)Furusato E, Hidayat AA, Man YG, Auerbach A, Furusato B, Rushing EJ 
InstitutionDepartment of Neuropathology and Ophthalmic Pathology, Armed Forces Institute of Pathology, Washington, DC 20306-6000, USA.
SourceArch Ophthalmol 2009 Aug; 127(8):964-9.
MeSHAdolescent
Adult
Aged
Aged, 80 and over
Antigens, Neoplasm
Child
Child, Preschool
Conjunctival Diseases
Conjunctival Neoplasms
Dysplastic Nevus Syndrome
Female
Humans
Immunoenzyme Techniques
Male
Melanoma
Melanosis
Middle Aged
Neoplasm Proteins
Nevus, Pigmented
Proto-Oncogene Proteins c-bcl-2
S100 Proteins
Tumor Markers, Biological
WT1 Proteins
Young Adult
AbstractOBJECTIVE: Recent studies indicate that WT1 and Bcl2 protein are detected in melanocytic lesions of the skin. We examined, for the first time, WT1 and Bcl2 expression in a variety of conjunctival melanocytic lesions to evaluate their diagnostic utility compared with other melanocytic markers.
METHODS: Protein expression and localization of WT1 and Bcl2 were studied by means of immunolabeling and semiquantification in 123 conjunctival melanocytic lesions (71 benign nevi, 21 atypical nevi, 11 primary acquired melanosis, and 20 malignant melanomas). Ancillary immunohistochemical studies were performed with Bcl2, S100, HMB45, and Melan A antibodies.
RESULTS: WT1 showed a graded increase in expression in lesions with increasing atypia. Higher mean numbers of WT1-positive cells correlated with increasing atypia in melanocytes. In all cases, Bcl2 expression was positive and more robust than was S100, HMB45, or Melan A expression. WT1 and HMB45 frequently showed diffuse and strong staining in atypical nevi, primary acquired melanosis with atypia, and malignant melanomas compared with benign lesions.
CONCLUSIONS: Bcl2 is a highly sensitive immunohistochemical marker for melanocytic tumors of the conjunctiva; HMB45 and WT1 staining distinguishes benign from malignant lesions.
CLINICAL RELEVANCE: Our results show that HMB45 and WT1 immunolabeling is helpful in the evaluation of conjunctival melanocytic lesions. Accordingly, we recommend the development of an immunohistochemical panel to classify these lesions.
Languageeng
Pub Type(s)Journal Article
PubMed ID19667332
  
Advertise on this site.